OPERAPLRG-10: Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell

Sponsor
Polish Lymphoma Research Group (Other)
Overall Status
Terminated
CT.gov ID
NCT03229382
Collaborator
Roche Pharma AG (Industry)
1
2
1
20.6
0.5
0

Study Details

Study Description

Brief Summary

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).
Actual Study Start Date :
May 14, 2018
Actual Primary Completion Date :
Jan 31, 2020
Actual Study Completion Date :
Jan 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22

Drug: Obinutuzumab
Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
Other Names:
  • Gazyvaro
  • GA101
  • Outcome Measures

    Primary Outcome Measures

    1. MRD negativity defined as a MRD level [2 months after obinutuzumab treatment]

      Molecular response rate (molRR) defined as a rate of molecular response with at least 10-4 sensitivity level assessed by quantitative RQ-PCR

    Secondary Outcome Measures

    1. Progression-free survival (PFS) [3 years and 2 month]

      defined as the time from the date of the first obinutuzumab infusion to disease progression or relapse, as determined by the investigator using the Lugano Classification or death from any cause after the last dose of study drug

    2. Time to molecular relapse [3 years and 2 month]

      as the time from the date of the first obinutuzumab infusion to the first occurrence of molecular disease relapse

    3. Overall survival (OS) [3 years and 2 month]

      defined as the time from the date of the initiation of the first line treatment to the death from any reason

    4. Time to relapse/progression [3 years and 2 month]

      defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse, as determined by the investigator using the Lugano Classification

    5. Event-free survival (EFS) [3 years and 2 month]

      defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse (as determined by the investigator using the Lugano Classification), death from any reason, start of the another anti-lymphoma treatment, SAE preventing continuation of the protocol treatment

    6. Health status measured with EQ-5D from EuroQoL Group [3 years and 2 month]

      with EQ-5D from EuroQoL Group

    7. Treatment tolerability assessment [3 years and 2 month]

      reporting of serious adverse events (SAEs), adverse events (AEs) and adverse events of special interest

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with evidence of MCL molecular relapse in peripheral blood or/and bone marrow,

    • Diagnosis of mantle cell lymphoma confirmed by histopathology

    • Presence of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion gene as a molecular marker used for minimal residual disease (MRD) assessment,

    • Patients in CR/PR after first-line treatment with myeloablative consolidation and ASCT,

    • Patients without evidence of mantle cell lymphoma progression/relapse according to the Lugano Classification criteria (2014),

    • ECOG performance status ≤ 2,

    • Signed patient's informed consent form,

    • Survival prognosis > 6 months,

    • Women of childbearing potential must have a negative pregnancy test result prior to initiation of treatment with the study medication and must consent to undergo pregnancy tests during the treatment period.,

    • Women of child-bearing potential must consent either to sexual abstinence or to using effective contraception (that results in a failure rate of < 1% per year) while receiving the study medication and for 18 months after its discontinuation,

    • Men must consent either to using an acceptable contraception method (that results in a failure rate of < 1% per year) or continued sexual abstinence while receiving the study medication and for 6 months after its discontinuation.

    Exclusion Criteria:
    • Central nervous system involvement,

    • Chemotherapy, radiation therapy or any other antineoplastic treatment (including steroids, monoclonal antibodies or medications at the stage of clinical studies, before receiving marketing authorisation) after ASCT and before administration of the study medication,

    • Major surgery within 28 days prior to the study treatment initiation,

    • Renal impairment (plasma creatinine concentration > 1.5 × upper limit of normal and/or creatinine clearance ≤ 40 ml/h),

    • Hepatic impairment (total bilirubin concentration > 1.5 × upper limit of normal, AST and ALT > 2.5 × upper limit of normal),

    • Hb< 9 g/dl, ANC < 1.5 G/l, platelets < 75 G/l,

    • International normalized ratio (INR) > 1.5,

    • Clinically significant heart disease, including uncontrolled arrhythmias, unstable coronary artery disease, serious congestive circulatory failure (NYHA III-IV), myocardial infarction within 6 months before enrolment,

    • Other comorbidities, not responding to treatment, including, but not limited to: hematopoietic system diseases, gastrointestinal system diseases, endocrine system diseases, respiratory system diseases, neurological diseases, cerebral diseases and mental diseases that could affect compliance with the protocol or interpretation of results,

    • Active infections (viral, bacterial, fungal),

    • Coexistence of another neoplasm or a history of neoplastic disease (except for adequately treated basal cell carcinoma or squamous cell skin carcinoma, in situ cervical cancer or other neoplasm if the patient is in complete remission after at least 5 years of treatment discontinuation),

    • Active HIV, HBV or HCV infection,

    • Positive test results for chronic hepatitis B. All patients must be tested for both HBsAg and HBcAb at screening, if either of the tests is positive, the patient is not eligible for inclusion in the trial. Patients who have protective titers of HBsAb after vaccination are eligible provided they are negative for both HBsAg and HBcAb,

    • Positive testing for hepatitis C (hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA,

    • Vaccination with live vaccines within 28 days prior to start of the preemptive treatment,

    • Known or suspected hypersensitivity to the study medication,

    • Women who are pregnant or breastfeeding.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centrum Onkologii - Instytut im. Marii Skłodowskiej- Curie Klinika Nowotworów Układu Chłonnego Warszawa Poland 02-781
    2 Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytetu Medycznego Wrocław Poland 50-369

    Sponsors and Collaborators

    • Polish Lymphoma Research Group
    • Roche Pharma AG

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Polish Lymphoma Research Group
    ClinicalTrials.gov Identifier:
    NCT03229382
    Other Study ID Numbers:
    • ML29157
    • 2015-005439-41
    First Posted:
    Jul 25, 2017
    Last Update Posted:
    Jan 13, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Polish Lymphoma Research Group
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2022